Retatrutide vs Tirzepatide vs Semaglutide

Semaglutide, tirzepatide, and retatrutide all work through the same broad family of gut-hormone receptors, but they aren't interchangeable — one targets a single receptor, one targets two, and one targets three and isn't approved for anyone to use yet. Here's what the actual trial numbers say.

Three drugs dominate the weight-loss conversation in 2026, and all three work through overlapping gut-hormone receptor pathways — but only two of them are legal to prescribe. Semaglutide (Ozempic, Wegovy) came first, built around a single receptor target with roughly a decade of trial and real-world data behind it. Tirzepatide (Mounjaro, Zepbound) added a second receptor and, in head-to-head data, produced larger average weight loss. Retatrutide goes a step further, activating three receptors at once, and has posted the largest weight-loss numbers of any incretin therapy tested so far — first in a Phase 2 trial, and now in Phase 3 results reported through 2026. The catch is that retatrutide isn't FDA-approved, isn't available by prescription anywhere, and has no long-term safety data outside its trial population. This is a straight comparison of what each drug actually targets, what the trials actually show, and where each stands on approval, side effects, and cost as of mid-2026.

How the three compounds differ mechanistically

Semaglutide is a GLP-1 receptor agonist and nothing else — a modified analog of human glucagon-like peptide-1 that binds GLP-1 receptors on pancreatic beta cells, the hypothalamus, and the gut, slowing gastric emptying and reducing appetite while boosting glucose-dependent insulin release. Tirzepatide is a dual agonist: the same GLP-1 receptor activity, plus activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor on a single 39-amino-acid molecule. In the head-to-head SURPASS-2 trial, tirzepatide's 10 mg and 15 mg doses produced significantly greater weight loss and HbA1c reduction than semaglutide 1 mg over 40 weeks in people with type 2 diabetes, which is the strongest direct evidence that adding GIP agonism does something beyond GLP-1 alone.⁸ Retatrutide adds a third target on top of that: glucagon receptor agonism. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation, a mechanism proposed to add a thermogenic, calorie-burning effect layered on top of the appetite suppression both other drugs already produce — which is why retatrutide gets called a "triple-G" or GGG agonist in the literature. All three are engineered with a fatty-acid or fatty-diacid side chain that binds albumin and extends their half-life to roughly 5–7 days, which is what allows once-weekly subcutaneous dosing across the whole class.

Weight-loss results compared: what the trials actually show

In the STEP 1 trial (1,961 adults with overweight or obesity, no diabetes), semaglutide 2.4 mg produced a mean 14.9% body-weight reduction versus 2.4% on placebo at 68 weeks, with 86.4% of treated participants losing at least 5% of body weight.¹ In SURMOUNT-1 (2,539 adults, same population type), tirzepatide 15 mg produced a mean 22.5% reduction versus 2.4% on placebo at 72 weeks, with 96% of that group losing at least 5%.² Retatrutide's Phase 2 trial (338 adults, 48 weeks) put its 12 mg dose at a mean 24.2% weight loss — already ahead of both approved drugs at a shorter trial duration.³ The bigger news landed in 2026, when Lilly's Phase 3 TRIUMPH-1 trial (2,339 participants, 80 weeks) reported 19.0% weight loss at 4 mg, 25.9% at 9 mg, and 28.3% at 12 mg — and a 104-week extension in participants with baseline BMI ≥35 who stayed on treatment reached 30.3% average loss (about 85 lbs) at the 12 mg dose.⁴ A second Phase 3 trial, TRIUMPH-4, tested retatrutide in adults with obesity and knee osteoarthritis and reported 28.7% weight loss at 12 mg over 68 weeks, alongside a 74–76% reduction in WOMAC knee-pain scores versus 40% on placebo.⁵ None of these trials directly compared all three drugs in the same population at the same time point, so the percentages aren't a perfect apples-to-apples ranking — but the pattern across every published trial to date is consistent: more receptors targeted has tracked with more weight loss.

Dosing and titration differences

All three drugs follow the same broad principle — start low and climb slowly to limit GI side effects — but the specific ladders differ:

1. Semaglutide (Wegovy): 0.25 mg weekly for 4 weeks, then 0.5 mg, 1 mg, and 1.7 mg in four-week steps, reaching the 2.4 mg maintenance dose around week 17.
2. Tirzepatide (Zepbound): 2.5 mg weekly for 4 weeks (starting dose only, not therapeutic), then increases of 2.5 mg roughly every 4 weeks — 5 mg, 7.5 mg, 10 mg, 12.5 mg — up to the 15 mg dose associated with the greatest mean weight loss in trials.
3. Retatrutide (trial protocols only): Phase 2 used a 12-week dose-escalation schedule up to the target dose; Phase 3 TRIUMPH trials used a similarly staged escalation toward 4 mg, 9 mg, or 12 mg targets, specifically designed to improve tolerability rather than reflecting any approved label — there is no real-world dosing standard because there's no approved product.

Approval status: FDA-approved vs. investigational

Semaglutide has the longest track record: the FDA approved Ozempic for type 2 diabetes in 2017 and Wegovy for chronic weight management in 2021, each with a full prescribing label covering dosing, warnings, and monitored side-effect rates.⁷ Tirzepatide followed a similar path — Mounjaro for type 2 diabetes in 2022, then Zepbound for chronic weight management on November 8, 2023, backed by the SURMOUNT-1 data above.⁶ Retatrutide has not completed that process. As of mid-2026, Lilly has reported positive topline Phase 3 results from TRIUMPH-1 (obesity) and TRIUMPH-4 (obesity with knee osteoarthritis), with several more TRIUMPH-program trials — covering type 2 diabetes, sleep apnea, chronic low back pain, and MASLD — expected to report through the rest of the year.⁴⁵ Lilly has not publicly confirmed a date for filing a New Drug Application, and no regulatory submission had been made as of this writing. That means retatrutide, whatever its trial numbers look like, is not a drug anyone can legally be prescribed today — it's a compound still working through the same multi-year FDA process semaglutide and tirzepatide already completed.

Side effect profiles compared

The three drugs share the same side-effect signature, because it comes from the same receptor family: gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are the most common adverse events for all of them, and they scale with dose. In Wegovy's weight-management trials, nausea occurred in roughly 44% of treated participants versus 16% on placebo, with vomiting around 25% versus 6%. Tirzepatide's label carries a similar GI profile plus the same boxed warning — thyroid C-cell tumors seen in rodent studies, contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 — along with warnings for acute pancreatitis and gallbladder disease that both approved drugs share. Retatrutide's Phase 3 TRIUMPH-1 data reported nausea in 28.6% to 42.4% of participants (rising by dose) versus 14.8% on placebo, diarrhea in 25.2% to 34.1% versus 13.5%, and vomiting in 10.6% to 25.3% versus 4.8% — with adverse-event discontinuation reaching 11.3% at the 12 mg dose, roughly double the placebo rate.⁴ Lilly has described retatrutide's overall safety pattern as consistent with the rest of the incretin class, but it's worth being direct about what that comparison can and can't support: these are three separate trials, in different populations, with different designs — not a controlled three-way comparison — and retatrutide specifically has no long-term (multi-year) safety or cardiovascular-outcomes data of the kind semaglutide and tirzepatide have already accumulated post-approval.

Cost and access differences

For the two approved drugs, manufacturer direct-pay programs have meaningfully changed the price picture in 2026: Lilly's LillyDirect Self Pay program prices Zepbound starting around $299/month for the 2.5 mg starter dose, $399 for 5 mg, and $449 for the 7.5–15 mg maintenance doses when refilled on schedule — well below the roughly $1,000+ list price without a manufacturer or insurance discount. Novo Nordisk's NovoCare Pharmacy prices Wegovy at a standard $349/month self-pay rate, down from a list price near $1,349, with a lower promotional rate for the two starting doses. Insurance coverage varies widely by plan and can bring costs lower still, or leave patients paying list price if weight-management drugs aren't a covered benefit. The compounded-drug workaround that filled gaps during 2022–2024 shortages has also largely closed: the FDA declared both drugs' shortages resolved (tirzepatide in October 2024, semaglutide in February 2025) and ended pharmacy compounding enforcement discretion for both by mid-2025, so mass-compounded versions of these two drugs are far less available than they were two years ago.⁹ Retatrutide sits outside this entire system — there is no manufacturer price, no insurance code, and no legal pharmacy channel, because there is no approved product. What is available is Lilly's clinical trial program (for eligible enrolled participants only) or unregulated "research chemical" sellers marketing retatrutide peptide vials online, which are not the material used in Lilly's trials, are not manufactured under any pharmaceutical quality standard, and carry the same contamination, mislabeling, and dosing-accuracy risks documented across the gray-market peptide space — see our guide on whether peptides are actually safe for what independent testing of those products has found.

Which one clinicians are actually prescribing in 2026

In practice, the prescribing decision is between exactly two drugs, because retatrutide isn't a legal option yet. Among semaglutide and tirzepatide, many clinicians default to tirzepatide when a patient can tolerate it and access allows, largely on the strength of SURMOUNT-1's larger average weight loss and the direct SURPASS-2 comparison showing it outperforming semaglutide 1 mg in people with type 2 diabetes.²⁸ That's not universal — some patients tolerate semaglutide's GI profile better, cost or insurance formularies push one drug over the other, or a patient is already stable on one and switching isn't worth the restart in titration. Retatrutide, for now, only comes up in the conversation as "what's coming" — no prescriber can legally write for it, and any patient sourcing it independently is doing so entirely outside medical supervision, using unregulated material, and outside the dosing and monitoring framework the TRIUMPH trials actually followed.

The bottom line

The pattern across all three drugs is consistent — more receptor targets has tracked with more average weight loss, from semaglutide's single GLP-1 target to tirzepatide's dual GIP/GLP-1 mechanism to retatrutide's triple GIP/GLP-1/glucagon combination. But mechanism and trial results are only half the picture. Semaglutide and tirzepatide are approved, prescribable, insurable drugs with years of post-market safety data behind their trial results. Retatrutide, despite genuinely impressive Phase 2 and Phase 3 numbers, is still an investigational compound with no approval, no legal access pathway, and no long-term safety record outside a monitored trial population. If you're on any GLP-1-based therapy — approved or not — tracking your actual dose, titration step, and side effects over time is one of the most useful things you can do for both your results and your next conversation with a prescriber; Peptide Me's dose calculator and titration log exist for exactly that. As always, this article is general information, not medical advice — talk to a licensed clinician about which option, if any, fits your specific health situation.

FAQ

References

Primary sources — PubMed / NEJM / The Lancet.

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
4. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release. 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
5. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). Press release. 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
6. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound/tirzepatide). Press Announcement. November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
7. U.S. Food and Drug Administration. Highlights of Prescribing Information: WEGOVY (semaglutide) injection. accessdata.fda.gov. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
8. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
9. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize